Campbell et al. reported that expression levels of TRF1 and TRF2 were increased in CML patients in the CP and in the accelerated phase (AP) but reduced to a level comparable to normal controls in the majority of patients in the BP. Here, TERF1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.